Ahmed Aboeata
Cardiovascular Disease · Omaha, NENPI 1376709808
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $446 of the $645 with a category attached, or 69.1%. 13 manufacturers reported payments, led by Astellas Pharma US Inc at 30.9% of the total. Reporting peaked in 2021 at $363 and has fallen 95.3% since, to $17 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NE, where the typical reported total is $1,663.
Across 21 payments — averaging $30.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$199
- Boston Scientific$93
- Abiomed$58
- Saranas, Inc.$46
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$43
- Pfizer$42
- plus $163 from 7 others
Across 1 payment — averaging $8000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$8K
What the payments were for
- Food & beverage$44669%
- Education$19931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $199 |
| Boston Scientific | 2 | $93 |
| Abiomed | 1 | $58 |
| Saranas, Inc. | 1 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $43 |
| Pfizer | 3 | $42 |
| Abbott | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| AstraZeneca | 2 | $31 |
| Boehringer Ingelheim | 1 | $17 |
| Novartis | 1 | $16 |
| Amgen | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$645 in reported general payments places this provider in the 20th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $267,987 |
| EliquisApixaban | 147 | $141,323 |
| EntrestoSacubitril/Valsartan | 117 | $113,682 |
| JardianceEmpagliflozin | 105 | $84,161 |
| XareltoRivaroxaban | 62 | $55,447 |
| FarxigaDapagliflozin Propanediol | 45 | $42,420 |
| Metoprolol Succinate | 310 | $3,516 |
| Potassium Chloride | 130 | $2,774 |
| Atorvastatin Calcium | 274 | $2,174 |
| Amiodarone Hcl | 37 | $1,215 |
| Rosuvastatin Calcium | 100 | $1,041 |
| Flecainide Acetate | 25 | $757 |
| Bumetanide | 32 | $732 |
| Lisinopril | 126 | $650 |
| Ezetimibe | 59 | $636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $42 | $409,310159 claims |
| NovartisEntresto | $16 | $113,682117 claims |
| Boehringer IngelheimJardiance | $17 | $84,161105 claims |
| AstraZenecaFarxiga | $31 | $42,42045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$945K
- Jeffrey CarstensOmaha$124K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Edward OlearyOmaha$36K
- Faris KhanOmaha$17K
- Michael PetersOmaha$13K
- Thomas PorterOmaha$11K
- Gregory PavlidesOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.